Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis
eLife · 2024
DOI: 10.7554/elife.97654 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Miki Kume und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan. Hauptthemen laut MEDLINE: Psoriasis, Semaphorins, Keratinocytes, Mice, Knockout. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Maruho.
Abstract (Originalsprache)
Psoriasis is a multifactorial disorder mediated by IL-17-producing T cells, involving immune cells and skin-constituting cells. Semaphorin 4A (Sema4A), an immune semaphorin, is known to take part in T helper type 1/17 differentiation and activation. However, Sema4A is also crucial for maintaining peripheral tissue homeostasis and its involvement in skin remains unknown. Here, we revealed that while Sema4A expression was pronounced in psoriatic blood lymphocytes and monocytes, it was downregulated in the keratinocytes of both psoriatic lesions and non-lesions compared to controls. Imiquimod application induced more severe dermatitis in Sema4A knockout (KO) mice compared to wild-type (WT) mice. The naïve skin of Sema4A KO mice showed increased T cell infiltration and IL-17A expression along with thicker epidermis and distinct cytokeratin expression compared to WT mice, which are hallmarks of psoriatic non-lesions. Analysis of bone marrow chimeric mice suggested that Sema4A expression in keratinocytes plays a regulatory role in imiquimod-induced dermatitis. The epidermis of psoriatic non-lesion and Sema4A KO mice demonstrated mTOR complex 1 upregulation, and the application of mTOR inhibitors reversed the skewed expression of cytokeratins in Sema4A KO mice. Conclusively, Sema4A-mediated signaling cascades can be triggers for psoriasis and targets in the treatment and prevention of psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Department of Neurocutaneous Medicine, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Research Department, Maruho Co, Ltd., Kyoto, Japan.
- Cutaneous Allergy and Host Defense, Immunology Frontier Research Center (iFReC), Osaka University, Osaka, Japan.
- Department of Plastic Surgery, Course of Organ Regulation Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Department of Plastic and Reconstructive Surgery, Kindai University, Osaka, Japan.
ORCID-Profile: Miki Kume, Shuichi Nakai, Rei Watanabe
Förderung
- Japan Society for the Promotion of Science
- Maruho
Zitieren
APA
Kume, M., Koguchi-Yoshioka, H., Nakai, S., Matsumura, Y., Tanemura, A., Yokoi, K., Matsuda, S., Nakamura, Y., Otani, N., Taminato, M., Tomita, K., Kubo, T., Wataya-Kaneda, M., Kumanogoh, A., Fujimoto, M., & Watanabe, R. (2024). Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis. eLife. https://doi.org/10.7554/elife.97654
Vancouver
Kume M, Koguchi-Yoshioka H, Nakai S, Matsumura Y, Tanemura A, Yokoi K, et al. Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis. eLife. 2024. doi:10.7554/elife.97654
BibTeX
@article{Kume2024,
author = {Kume, Miki and Koguchi-Yoshioka, Hanako and Nakai, Shuichi and Matsumura, Yutaka and Tanemura, Atsushi and Yokoi, Kazunori and Matsuda, Shoichi and Nakamura, Yuumi and Otani, Naoya and Taminato, Mifue and Tomita, Koichi and Kubo, Tateki and Wataya-Kaneda, Mari and Kumanogoh, Atsushi and Fujimoto, Manabu and Watanabe, Rei},
title = {Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.97654}
}
EUVIMED